argenx SE (argenx SE) EV-to-Revenue

: 15.11 (As of Today)

View and export this data going back to 2017. Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, argenx SE's enterprise value is $18,525 Mil. argenx SE's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $1,226 Mil. Therefore, argenx SE's EV-to-Revenue for today is 15.11.

The historical rank and industry rank for argenx SE's EV-to-Revenue or its related term are showing as below:

ARGX' s EV-to-Revenue Range Over the Past 10 Years
Min: 9.05 Med: 39.81 Max: 342.52
Current: 15.13

During the past 13 years, the highest EV-to-Revenue of argenx SE was 342.52. The lowest was 9.05. And the median was 39.81.

ARGX's EV-to-Revenue is ranked worse than
63.95% of 1032 companies
in the Biotechnology industry
Industry Median: 7.565 vs ARGX: 15.13

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-20), argenx SE's stock price is $360.06. argenx SE's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $21.34. Therefore, argenx SE's PS Ratio for today is 16.87.

argenx SE EV-to-Revenue Historical Data

The historical data trend for argenx SE's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

67.92

291.40

32.34

44.45

15.50

argenx SE Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue																44.45	32.73	23.81	29.33	15.50

Competitive Comparison

For the Biotechnology subindustry, argenx SE's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

argenx SE EV-to-Revenue Distribution

For the Biotechnology industry and Healthcare sector, argenx SE's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where argenx SE's EV-to-Revenue falls into.

argenx SE EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

argenx SE's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	18524.939	/	1226.316
	=	15.11

argenx SE's current Enterprise Value is $18,525 Mil.
argenx SE's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,226 Mil.

argenx SE (NAS:ARGX) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

argenx SE's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	360.06	/	21.343
	=	16.87

argenx SE's share price for today is $360.06.
argenx SE's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $21.34.

argenx SE EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of argenx SE's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

argenx SE (argenx SE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (NAS:ARGX) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

ARGX:Mexico ARGXb:UK 0QW0:UK 1AEA:Germany 1AE:Germany 1AE:Germany A1RG34:Brazil ARGX:Belgium ARGX:Austria

Address

Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB

Website

https://www.argenx.com

Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.